ViaCyte has obtained $10.6 million in financing that the company says would go toward its VC-01 device, which uses cells derived from human embryonic stem cells to treat patients with type 1 diabetes. The company already has tested the device in animals and hopes to launch human clinical studies next year, CEO Paul Laikind said.

Related Summaries